Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice
Full description
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy.
A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
72 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal